A genetic strategy to overcome the senescence of primary meningioma cell cultures

被引:43
作者
Baia, Gilson S.
Slocum, Alison L.
Hyer, Jeanette D.
Misra, Anjan
Sehati, Nouzhan
VandenBerg, Scott R.
Feuerstein, Burt G.
Deen, Dennis F.
McDermott, Michael W.
Lal, Anita
机构
[1] Univ Calif San Francisco, Brain Tumor Res Ctr, Dept Neurol Surg, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA
关键词
immortalization; meningioma; model systems; senescence; telomerase;
D O I
10.1007/s11060-005-9076-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Even though meningiomas are the second most common brain tumor in adults, little is known about the molecular basis of their growth and development. The lack of suitable cell culture model systems is an impediment to this understanding. Most studies on meningiomas rely on primary, early passage cell lines that eventually senesce or a few established cell lines that have been derived from aggressive variants of meningiomas. We have isolated three primary meningioma cell lines that are negative for telomerase activity. We can overcome the senescence of a Grade III derived meningioma cell line by expressing the telomerase catalytic subunit (hTERT), whereas Grade I meningioma cell lines require the expression of the human papillomavirus E6 and E7 oncogenes in conjunction with hTERT. Meningioma cell lines, immortalized in this manner, maintain their pre-transfection morphology and form colonies in vitro. We have confirmed the meningothelial origin of these cell lines by assessing expression of vimentin and desmoplakin, characteristic markers for meningiomas. Additionally, we have karyotyped these cell lines using array CGH and shown that they represent a spectrum of the genetic diversity seen in primary meningiomas. Thus, these cell lines represent novel cellular reagents for investigating the molecular oncogenesis of meningiomas.
引用
收藏
页码:113 / 121
页数:9
相关论文
共 36 条
[1]
Molecular characterization of desmosomes in meningiomas and arachnoidal tissue [J].
Akat, K ;
Mennel, HD ;
Kremer, P ;
Gassler, N ;
Bleck, CKE ;
Kartenbeck, J .
ACTA NEUROPATHOLOGICA, 2003, 106 (04) :337-347
[2]
Alterations of the tumor suppressor genes CDKN2A (p16INK4a), p14ARF, CDKN2B (p15INK4b), and CDKN2C (p18INK4c) in atypical and anaplastic meningiomas [J].
Boström, J ;
Meyer-Puttlitz, B ;
Wolter, M ;
Blaschke, B ;
Weber, RG ;
Lichter, P ;
Ichimura, K ;
Collins, VP ;
Reifenberger, G .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (02) :661-669
[3]
TELOMERE ELONGATION IN IMMORTAL HUMAN-CELLS WITHOUT DETECTABLE TELOMERASE ACTIVITY [J].
BRYAN, TM ;
ENGLEZOU, A ;
GUPTA, J ;
BACCHETTI, S ;
REDDEL, RR .
EMBO JOURNAL, 1995, 14 (17) :4240-4248
[4]
Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines [J].
Bryan, TM ;
Englezou, A ;
DallaPozza, L ;
Dunham, MA ;
Reddel, RR .
NATURE MEDICINE, 1997, 3 (11) :1271-1274
[5]
Aspects of the structure and assembly of desmosomes [J].
Burdett, IDJ .
MICRON, 1998, 29 (04) :309-328
[6]
Cellular senescence as a tumor-suppressor mechanism [J].
Campisi, J .
TRENDS IN CELL BIOLOGY, 2001, 11 (11) :S27-S31
[7]
Carlson KM, 1997, GENE CHROMOSOME CANC, V20, P419
[8]
Meningioma transcript profiles reveal deregulated notch signaling pathway [J].
Cuevas, IC ;
Slocum, AL ;
Jun, P ;
Costello, JF ;
Bollen, AW ;
Riggins, GJ ;
McDermott, MW ;
Lal, A .
CANCER RESEARCH, 2005, 65 (12) :5070-5075
[9]
DeVitis LR, 1996, HUM GENET, V97, P632
[10]
Gene therapy for meningioma: improved gene delivery with targeted adenoviruses [J].
Dirven, CMF ;
Grill, J ;
Lamfers, MLM ;
Van der Valk, P ;
Leonhart, AM ;
Van Beusechem, VW ;
Haisma, HJ ;
Pinedo, HM ;
Curiel, DT ;
Vandertop, WP ;
Gerritsen, WR .
JOURNAL OF NEUROSURGERY, 2002, 97 (02) :441-449